J&J’s Erda-iDRS Shows 89% Complete Response in NMIBC – Intravesical Erdafitinib System Advances to Phase II/III
Johnson & Johnson (J&J, NYSE: JNJ) announced positive Phase I results for Erda-iDRS, an investigational...
BeBetter Medicine’s Ifupinostat Wins NMPA Approval for PTCL Trial – First HDAC/PI3Kα Dual Inhibitor Enters First-Line Lymphoma Study
Guangzhou BeBetter Medicine Technology Co., Ltd (SHA: 688759) announced NMPA clearance to initiate a clinical...
Abbisko’s Irpagratinib Doses First Patient in Phase II HCC Trial – FGFR4 Inhibitor Plus Toripalimab/Bevacizumab Targets First-Line Liver Cancer
Abbisko Therapeutics Co., Ltd (HKG: 2256) announced first patient dosing in a Phase II clinical...
Junshi Biosciences Reports RMB 2.5 Billion 2025 Revenue – Toripalimab Drives 40% Drug Sales Growth as Losses Narrow
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) released 2025 financial results, recording RMB...
YolTech’s YOLT-202 Wins FDA Phase II/III Approval – In Vivo Base Editing Gene Therapy Targets Alpha-1 Antitrypsin Deficiency
YolTech Therapeutics announced FDA clearance to initiate an open-label, single-dose expansion Phase II/III clinical study...
GSK’s Arexvy Wins FDA Label Expansion – RSV Vaccine Now Covers High-Risk Adults Aged 18-49
GlaxoSmithKline (GSK, NYSE: GSK) announced FDA approval for a label expansion of its adjuvanted respiratory...
Biogen’s Salanersen Shows 75% NfL Reduction in SMA Phase Ib – Once-Yearly ASO Advances to Phase III
Biogen Inc. (NASDAQ: BIIB) presented supplemental Phase Ib data for salanersen, its investigational antisense oligonucleotide...
Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market
Kintor Pharmaceutical Limited (HKG: 9939) entered into a strategic cooperation agreement with Zhejiang Fonow Medicine...
Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing
Sino Biopharmaceutical (HKG: 1177) announced that TQB3454 Tablets, a Category 1 innovative drug developed by...
CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces
China Medical System Holdings (CMS; HKG: 0867) announced that first prescriptions of Ruxolitinib Phosphate Cream...
Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic
Shanghai Essight Biotechnology Co., Ltd. announced that ES502 Injection has received FDA approval to proceed...
APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio
APC Group and Youcare Pharmaceutical Group (SHA: 688658) signed a strategic cooperation framework agreement establishing...
WuXi Biologics Partners with Earendil Labs – Integrated CDMO Services for Bispecific Antibodies and ADCs Targeting Autoimmune and Oncology Indications
WuXi Biologics (HKG: 2269) announced a strategic cooperation agreement with Earendil Labs, the overseas subsidiary...
Everest Medicines Reports Positive Phase IIa Data for VIS-101 – Dual VEGF-A/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD
Everest Medicines (HKG: 1952) announced positive topline results from its Phase IIa study of VIS-101,...
Luye Pharma Signs Strategic Partnership with Sinopharm – Mimeixin Distribution Deal Targets China’s Severe Pain Market
Luye Pharma Group Limited (HKG: 2186) announced a strategic cooperation agreement with Sinopharm Group Co.,...
Porton Advanced Partners with T&L Biotechnology – CGT One-Stop Solution Targets Global Cell and Gene Therapy Market
Porton Advanced, a subsidiary of Porton Pharma Solutions, Ltd, announced a strategic partnership with T&L...
China NMPA Approves World’s First Invasive BCI Medical Device – Brain-Computer Interface Hand Motor System Targets Spinal Cord Injury Patients
China’s National Medical Products Administration (NMPA) granted registration approval for the “Implantable Brain-Computer Interface Hand...
Changchun GeneScience’s GenSci128 Wins FDA Orphan Drug Designation – TP53 Y220C Reactivator Targets Pancreatic Cancer
Changchun GeneScience Pharmaceutical Inc. announced that GenSci128 tablets, its independently developed selective TP53 Y220C mutation...
Sino Biopharm’s TQB3205 Wins NMPA Approval – First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers
Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB3205, an orally administered Pan-KRAS inhibitor independently developed...
Sandoz Forms Global Biosimilars Unit – Metzger-Led Division Targets Accelerated Portfolio Growth
Sandoz (SWX: SDZ), the Swiss generic drug giant, announced the formation of a dedicated global...